Merit Medical withdraws WRAPSODY TPT application; CMS deferral delays payment to Jan 2027

MERIT MEDICAL SYSTEMS INC

CMS deferred Merit's Transitional Pass-Through incremental payment application for WRAPSODY CIE to CY2027 rule; Jan 1, 2027 earliest effective date.
Merit withdraws TPT application and will immediately begin full U.S. commercialization of WRAPSODY CIE.
CEO cites strong 24-month efficacy data from WRAPSODY WAVE Trial as key differentiator vs. competitors.
FY2025 U.S. WRAPSODY CIE revenue forecast remains $2M-$4M.
Device received FDA premarket approval Dec 2024; approved by Health Canada Apr 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.